





# *Medicina nuclear*

*Denise Mascagni*

















GAMA CÂMARA

PET CT









# Terapia + diagnóstico = TERANÓSTICO

Um novo passo da Medicina avançada


A principal finalidade da Medicina Nuclear Teranóstica é utilizar um radiofármaco com propriedades diagnósticas (contendo um radioisótopo emissor de fótons gama de baixa energia) para conhecer a extensão da doença e posteriormente substituir esse radioisótopo por um com propriedades terapêuticas (radioisótopo emissor de fótons de alta energia) que será ligado ao mesmo fármaco para tratamento.

## ESTIMATIVA

**INCA estima 704 mil casos de câncer por ano no Brasil até 2025**

Mama, em mulheres, e próstata, em homens, continuam sendo os tipos da doença com maior incidência no País

# Molécula de PSMA



Radioisótopos para diagnóstico

$^{18}\text{F}$

$^{68}\text{Ga}$

Radioisótopos para terapia


$^{177}\text{Lu}$

$^{225}\text{Ac}$

Extracelular


Intracelular

**A**



12/2014  
PSA = 2,923 ng/mL

**B**



3x  
 $^{225}\text{Ac}$ -PSMA

7/2015  
PSA = 0.26 ng/mL

**C**




1x  
 $^{225}\text{Ac}$ -PSMA

9/2015  
PSA < 0.1 ng/mL



Resposta marcante de metástases de câncer de próstata tratadas com  $\text{Ac}^{225}$

# TNE E MEDICINA NUCLEAR: TERANÓSTICO





“O nosso produto é a vida”

*Denise Mascagni - P&D Medical*

Contato: (11) 989020954

e-mail: [denise.mascagni@medicalald.com.br](mailto:denise.mascagni@medicalald.com.br)